PDS Biotechnology Corp — Director's Dealing 2017

Aug 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-08-29

Reporting Person: MARCHIO ALBERT N II (Chief Accounting & Adm Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-29	Common Stock	S	2500	$10.42	Disposed	3361	Direct

Footnotes

F1: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.47 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.